Emergent BioSolutions reported $679.5M in Current Assets for its fiscal quarter ending in December of 2023.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Akebia Therapeutics USD 220.78M 8.77M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
ANI Pharmaceuticals USD 902.82M 77.39M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Exelixis USD 1.32B 70.8M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Ironwood Pharmaceuticals USD 225.99M 26.79M Sep/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck USD 38.94B 2.26B Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Pacira USD 10.3B 9.68B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Sanofi EUR 33.21B 1.68B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025